Expert Opinion on Drug Discovery
August 8, 2022
Andrzej Pilc, Agata Machaczka, Paweł Kawalec et al.
20 citations
INTRODUCTION: Major depressive disorder remains a prevalent world-wide health problem. Currently available antidepressant medications take weeks of dosing, do not produce antidepressant response in all patients, and have undesirable ancillary effects. AREAS COVERED: The present opinion piece focuses on the major inroads to the creation of new antidepressants. These include N-methyl-D-aspartate...
The International Journal of Neuropsychopharmacology
August 5, 2022
J. Phillips, A. van Geel, P. Burhunduli et al.
Abstract Background Subanesthetic ketamine infusions can elicit rapid and sustained antidepressant effects, yet the potential cognitive impact of ketamine has not been thoroughly examined. This study measured changes in objective and subjective cognitive function following repeated ketamine treatment. Methods Thirty-eight patients with treatment-resistant depression were administered cognitive...
Psychological Reports
August 1, 2022
Anja Roemer, Anna Sutton, Oleg N. Medvedev
Objectives: Pressures in daily life limit one’s ability to be authentic and research shows that inauthenticity can be detrimental to mental health. Mindfulness is known to have a protective effect on mental health through an accepting and nonjudgmental stance. This study aimed to establish whether mindfulness buffers the relationship between inauthenticity and depression. Method: A...
Acta Psychiatrica Scandinavica
August 1, 2022
Helen Liu, Jaimie Kerzner, Ilya Demchenko et al.
To systematically review published research studies and ongoing clinical trials investigating nitrous oxide (N2 O) in psychiatric disorders, providing an up-to-date snapshot of the clinical research landscape. A comprehensive literature search was conducted for studies published until June 2021 using the OVID databases (MEDLINE, Embase, APA PsycInfo) and the clinical trial registries...
Australasian Psychiatry
August 1, 2022
Stephen Rosenman
2 citations
Background Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most research has been done, costs less than $20 per dose. Research shows that intranasal esketamine is less effective and has more unwanted effects than injected...
Zeitschrift für Phytotherapie
August 1, 2022
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.1056/ NEJMoa2032994
Journal of Palliative Medicine
August 1, 2022
William E Rosa, Zachary Sager, Megan Miller et al.
49 citations
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...
CNS Spectrums
July 29, 2022
Ibrahim Turkoz, Oliver Lopena, Giacomo Salvadore et al.
6 citations
Abstract Objective To assess the likelihood of attaining response/remission of depressive symptoms with esketamine nasal spray (ESK) plus standard of care (SoC) vs placebo nasal spray (PBO) plus SoC at 4 weeks in patients with major depressive disorder and active suicidal ideation with intent (MDSI) without early response. Methods A post hoc analysis of pooled data from ASPIRE I and ASPIRE II...
Frontiers in Psychiatry
July 25, 2022
Maximilian Carter, Kassandra Solsrud, Nicholas Mischel
IntroductionAbout one third of patients with major depressive disorder (MDD) have treatment resistant depression (TRD). The difficulty of treating TRD especially in those with suicidal ideation and psychotic features demands treatments that are fast-acting, safe, and effective. Limited access, lack of viable options, and incomplete characterization of rapid-acting antidepressants has prevented...
Frontiers in Pharmacology
July 25, 2022
Kurt Stocker, Matthias Hartmann, Steffen Reissmann et al.
Background: Cognition that is not dominated by thinking in terms of opposites (opposite diminishing) or by making judgments (non-judging) can be found both in Buddhist/mindfulness contexts and in mental states that are fostered by dissociative psychedelics (N-methyl-D-aspartate antagonists) such as ketamine. Especially for the Buddhist/mindfulness case, both opposite diminishing and non-judging...
Frontiers in Psychiatry
July 22, 2022
M. Cigognini, A. G. Guirado, Denise van de Meene et al.
Objective Ketamine, an N-methyl D-aspartate (NMDA) receptor antagonist, can promote rapid action in the management of individuals with treatment-resistant depression (TRD) at sub-anesthetic doses. However, few studies have investigated the long-term use of ketamine administered intravenously (IV) and intranasally (IN). We report the design and rationale of a therapeutic trial for assessing the...
Frontiers in Psychiatry
July 22, 2022
Lai Fong Chan, Luke Sy-Cherng Woon, Nuur Asyikin Mohd Shukor et al.
2 citations
A significant proportion of patients with treatment-resistant depression do not attain functional recovery despite administration of multiple steps of pharmacotherapeutic strategies. This highlights the elusiveness of meeting unmet needs in existing pharmacotherapies for treatment-resistant depression. There is accumulating evidence that antidepressant agents involving the glutamatergic system...
Scandinavian Journal of Psychology
July 19, 2022
Qiang Xie, Ye Guan, Stefan G Hofmann et al.
The benefits of mindfulness-based interventions to alleviate anxiety and depression have been supported by many studies. Given the effectiveness of mindfulness-based interventions on anxiety and depression, the underlying mechanisms need to be explored. Using a randomized waitlist-controlled design, this study investigated whether anxiety sensitivity was a potential mechanism for the impact of...
Biological Psychiatry
July 15, 2022
Randall J Ellis, Anissa Bara, Claudia A Vargas et al.
Cannabis remains one of the most widely abused drugs during pregnancy. In utero exposure to its principal psychoactive component, Δ9-tetrahydrocannabinol (THC), can result in long-term neuropsychiatric risk for the progeny. This study investigated epigenetic signatures underlying these enduring consequences. Rat dams were exposed daily to THC (0.15 mg/kg) during pregnancy, and adult male...
PLoS One
July 14, 2022
Ellentika Chayadi, N. Baes, L. Kiropoulos
Objective Mindfulness-based interventions (MBIs) are increasingly being integrated into oncological treatment to mitigate psychological distress and promote emotional and physical well-being. This review aims to provide the most recent evaluation of Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Cancer Recovery (MBCR) treatments, in...
Cannabis
July 11, 2022
Mitch Earleywine, Maha N. Mian, Brianna R. Altman et al.
11 citations
Psychedelic-assisted psychotherapy has established antidepressant effects. Cannabis users appear to expect high doses administered in a session much like psychedelic-assisted psychotherapy to create comparable subjective effects. The current studies explored expectations of antidepressant effects of such cannabis-assisted sessions to replicate and extend previous work. Users not only expected a...
Frontiers in Psychiatry
July 8, 2022
Maud Rothärmel, Cherifa Benosman, Wissam El-Hage et al.
31 citations
Introduction: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in patients having TRD with comorbid PTSD. Materials and...
Journal of Cancer Research and Clinical Oncology
July 5, 2022
Wei-Min Liu, Juan Liu, Lan Ma et al.
Purpose The objective of this study is to explore the effects of a mindfulness yoga treatment on emotional disorders, fatigue, pain, and health-related quality of life in early-stage breast cancer patients. Methods The eligible 136 participants were randomly assigned 1:1 to the experimental group (mindfulness yoga + conventional care) and the control group (conventional care). The hospital...
International Journal of Bipolar Disorders
July 5, 2022
Oliver G. Bosch, Simon Halm, Erich Seifritz
35 citations
Abstract This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory...
The World Journal of Biological Psychiatry
July 4, 2022
Monika Dmitrzak-Weglarz, M. Tyszkiewicz-Nwafor, Filip Rybakowski et al.
Abstract Objectives This study attempts to assess the concentration of two opposite-acting adipokines (anti-inflammatory adiponectin and pro-inflammatory resistin) in antidepressant-resistant patients undergoing ketamine infusion (KI) and electroconvulsive therapy (ECT). Methods The study group comprised 52 patients hospitalised due to episodes of depression in the course of bipolar disorders....